Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571295 | 1.00 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL234030 | 0.87 | TSHR (0.60) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL17022287 | 0.86 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL289045 | 0.86 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL2313707 | 0.84 | CA12 (0.70) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL31083917 | 0.84 | CA12 (0.70) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL6049412 | 0.83 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL21857616 | 0.83 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL31189997 | 0.83 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL961701 | 0.83 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-26 | — | — | US | disclosed |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4364737-A2 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4229056-B1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116802181-A | Triazolopyridine compounds as kinase inhibitors | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4229056-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022086828-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009042907-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042907-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-2027088-A2 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | ALDH1A1 4270/4885SMN1; SMN2 4117/4885GABRA1 3179/4885 |
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | ALDH1A1 690/4885SMN1; SMN2 4778/4885GABRA1 467/4885 |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | ALDH1A1 4270/4885SMN1; SMN2 4117/4885GABRA1 3179/4885 |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | ALDH1A1 4270/4885SMN1; SMN2 4117/4885GABRA1 3179/4885 |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | ALDH1A1 4270/4885SMN1; SMN2 4117/4885GABRA1 3179/4885 |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | ALDH1A1 1547/4885SMN1; SMN2 1/4885GABRA1 615/4885 |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | ALDH1A1 4270/4885SMN1; SMN2 4117/4885GABRA1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.